



US009636305B2

(12) **United States Patent**
Fathi et al.(10) **Patent No.:** US 9,636,305 B2
(45) **Date of Patent:** May 2, 2017(54) **ANTIEMETIC EXTENDED RELEASE SOLID DOSAGE FORMS**(71) Applicant: **RedHill Biopharma Ltd.**, Tel Aviv (IL)(72) Inventors: **Reza Fathi**, HoHoKus, NJ (US);
Gilead Raday, Palo Alto, CA (US)(73) Assignee: **RedHill Biopharma Ltd.**, Tel Aviv (IL)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 68 days.

(21) Appl. No.: **14/212,694**(22) Filed: **Mar. 14, 2014**(65) **Prior Publication Data**

US 2014/0271887 A1 Sep. 18, 2014

Related U.S. Application Data

(60) Provisional application No. 61/782,395, filed on Mar. 14, 2013.

(51) **Int. Cl.**

A61K 9/28 (2006.01)
A61K 31/4178 (2006.01)
A61K 9/24 (2006.01)
A61K 9/20 (2006.01)

(52) **U.S. Cl.**

CPC **A61K 9/286** (2013.01); **A61K 9/209** (2013.01); **A61K 9/2886** (2013.01); **A61K 31/4178** (2013.01); **A61K 9/2013** (2013.01); **A61K 9/2054** (2013.01); **A61K 9/2846** (2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,720,353 A	1/1988	Bell
6,090,411 A	7/2000	Pillay et al.
6,500,457 B1	12/2002	Midha et al.
6,517,868 B2	2/2003	Fassihi et al.
6,733,789 B1	5/2004	Stark et al.
6,936,275 B2	8/2005	Fassihi et al.
7,229,642 B2	6/2007	Fassihi et al.
2002/0044962 A1	4/2002	Cherukuri et al.
2002/0071863 A1	6/2002	Dong et al.
2004/0147510 A1	7/2004	Landa et al.
2005/0131045 A1	6/2005	Aronhime et al.
2007/0082857 A1	4/2007	Sawa
2007/0190141 A1	8/2007	Dely
2008/0004260 A1	1/2008	Singh
2008/0044470 A1	2/2008	Peterait et al.
2008/0113021 A1	5/2008	Shen
2008/0200508 A1	8/2008	Rariy et al.
2008/0299197 A1	12/2008	Toneguzzo et al.
2010/0028420 A1	2/2010	Hardy
2010/0196291 A1	8/2010	Halimi
2010/0196472 A1	8/2010	Hirsh et al.
2010/0291208 A1	11/2010	Wang et al.
2011/0003005 A1	1/2011	Venkatesh et al.

2011/0160264 A1 6/2011 Myers et al.
2012/0010213 A1 1/2012 Chandavarkar et al.
2013/0156854 A1 6/2013 Kulkarni et al.
2014/0271851 A1 9/2014 Fathi et al.

FOREIGN PATENT DOCUMENTS

WO 03/013482 A1 2/2003
WO 03009829 A2 2/2003
WO 2008065424 A1 6/2008
WO 2009/118763 A1 10/2009

OTHER PUBLICATIONS

Streubel, A. et al. Bimodal drug release achieved with multi-layer matrix tablets: transport mechanisms and device design, Journal of Controlled Release, vol. 69 (2000) pp. 455-468.

Prasad, B. et al. Prospective Trial of Efficacy and Safety of Ondansetron and Fluoxetine in Patients with Obstructive Sleep Apnea Syndrome, Sleep, vol. 33, No. 7, 2010 pp. 982-989.

Recupero, A. Novel Formulations to Improve the Control of Emesis, EURAND Pharmaceutical Technologies Advertorial, Oct. 2010, 1 page.

PCT/IB 14/01633 filed Mar. 14, 2014, International Search Report and the Written Opinion of the International Searching Authority dated Jan. 21, 2015, 17 pages.

Opadry YS-1-7006 Technical Data Sheet (2011).

Venkatesh et al., "Formulation Optimisation of Ondansetron Floating Tablets for Gastric Retention", International Journal of Advanced Pharmaceuticals, 1 (1), 2011, pp. 11-18.

"Using METHOCEL Cellulose Ethers for Controlled Release of Drugs in Hydrophilic Matrix Systems", The Dow Chemical Company, Jul. 2000.

"METHOCEL Cellulose Ethers in Aqueous Systems for Tablet Coating", The Dow Chemical Company, Jul. 2002.

Patka, "Randomized Control Trial of Ondansetron vs. Prochlorperazine in Adults in the Emergency Department", West. J. Emergency Med., vol. XII, No. 1, Feb. 2011.

(Continued)

*Primary Examiner — Tigabu Kassa**(74) Attorney, Agent, or Firm — Greenberg Traurig, LLP*(57) **ABSTRACT**

A solid oral dosage form includes a core comprising a non-ionic polymer matrix, a first amount of a first antiemetic drug or a pharmaceutically acceptable salt thereof dispersed within the matrix, and a salt dispersed within the matrix; a first seal coat of a non-ionic polymer matrix surrounding the core; and an immediate release drug layer surrounding the first seal coat, wherein the immediate release drug layer comprises a non-ionic polymer and a second amount of a second antiemetic drug or a pharmaceutically acceptable salt thereof dispersed therein, wherein the drug layer is sufficiently designed to release the second amount of the antiemetic drug over a period of at least 1 hour, wherein the solid oral dosage form is sufficiently designed to release the first amount of the first antiemetic drug and the second amount of the second antiemetic drug over a minimum period of 16 hours.